In fact, despite that decision, compounding pharmacies still have considerable freedom under FDA regulations to fill prescriptions for GLP-1 drugs
has made finding possible causes of autism a priority for research, including in May 2025 launching the $50 million Autism Data Science Initiative, and in September 2025 issuing a warning about the potential link between acetaminophen and autism
Through a mechanism backed by over 6,000 participants in Phase 3 trials, FDA approval, and reproducible 1521% mean body weight reductions
The company is also planning to launch a pen device, likely in April, priced at 4,000 4,500 monthly
A systematic review of experimental and clinical studies on the pharmacology of glycyrrhizin and its derivatives